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ulated immune responses, possibly occurring in susceptible
individuals with a genetic predisposition. Persistent stimu-
lation by cytokines such as IFN-γ andTNF-α could promote
dietary or autoantigen presentation to T cells and B cells
followed by production of specific antibodies. Complex-
ing of antibodies to local or circulating antigens presum-
ably leads to chronic immune complex deposition in the
glomerulus, where complement activation could promote
hypocomplementaemia. A membranoproliferative pattern
of glomerulonephritis usually indicates the presence of a
chronic immune stimuluswith continuous or episodic levels
of circulating immune complexes [15]. In our case, the close
temporal association between initiation of a gluten-free diet
and the resolution of proteinuria (without use of immuno-
suppressive therapy and despite tapering of angiotensin en-
zyme inhibitor) strongly supports an aetiologic association.
This case illustrates that MPGN may precede overt clinical
evidence of CS, via subclinical disease mediated by chronic
antigen stimulation. Importantly, CS-associatedMPGN can
resolve clinically following initiation of gluten-free diet,
without resort to immunosuppressive therapy.
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Abstract
Complement factor H (CFH) mutation is one of the causes
of atypical haemolytic uraemic syndrome (aHUS). Patients
with CFHmutation-associated aHUS progress often to end-
stage renal disease despite plasma exchange therapy. When
such patients are transplanted, aHUS recurs almost invari-
ably and causes graft failure making the rationale of single
kidney allograft transplantation questionable. Since CFH
is synthesized mostly by the liver, combined liver–kidney
transplantation has been recommended. However, fatal out-
comes have been reported using this strategy. We report a
case of successful single kidney allograft transplantation in
a patient with a CFH gene mutation (R1210C), who had
end-stage renal failure after three flares of aHUS treated
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with plasma exchange. He received peri- and postoperative
infusions of fresh frozen plasma, which to date has pre-
vented recurrence of the disease. He has preserved renal
function 1-year post-transplant.
Keywords: complement factor H; haemolytic uraemic syndrome;
kidney transplantation
Background
Haemolytic uraemic syndrome (HUS) is a clinical syn-
drome characterized by microangiopathic haemolytic
anaemia, thrombocytopenia and acute renal failure [1]. Pae-
diatric cases are often caused by shiga-like toxin-producing
Escherichia coli. However, atypical cases may occur with
a manifestation at all ages, showing a tendency to relapse,
to occur in families and to have a poor outcome (= atypi-
cal HUS, aHUS). Recent evidence has indicated that many
of such aHUS cases are associated with mutations in pro-
teins of the complement system. Mutations in the comple-
ment factor H (CFH) gene account for ∼10–30% of cases
of familial or recurrent HUS [2–4]. CFH is synthesized
mostly by the liver. It is amajor regulator of the complement
cascade by inactivation of C3b in the fluid phase and on host
cells as well [5]. Patients, who have a mutation responsible
for a loss of binding of CFH on cell surfaces, are at risk of
developing endothelial cell damage when the complement
is activated. Plasma exchange therapy or plasma infusions
may improve the clinical course of aHUS related to CFH
gene mutations, possibly by supplementing large quantities
of normal CFH [6]. However, the disease recurs and many
patients finally progress to end-stage renal disease (ESRD)
after having had several relapses [7].
Atypical HUS almost invariably recurs in kidney grafts
and causes graft failure, making the rationale of single kid-
ney allograft transplantation questionable [8]. Given that
CFH is mostly synthesized by the liver, combined liver–
kidney transplantation may correct the complement abnor-
mality associated with mutations in the gene encoding CFH
and prevent recurrence of aHUS [9]. Recently, combined
liver–kidney transplantation has been recommended as the
preferred therapeutic regimen for patients with ESRD due
to aHUS associated with mutations in genes encoding com-
plement regulatory proteins such as CFH and complement
factor I [10]. However, some fatal outcomes have been re-
ported using this strategy (reviewed in [8]).
We report a case of successful single kidney allograft
transplantation in a patient with aHUS due to a CFH gene
mutation treated with multiple infusions of fresh frozen
plasma (FFP) peri- and postoperatively.
Case report
The clinical course before and after transplantation is sum-
marized in Figure 1A and B. On August 1999, following
a prolonged upper respiratory tract infection with fever
but no diarrhoea, a 23-year-old man developed acute re-
nal failure associated with microangiopathic haemolytic
anaemia and thrombocytopenia, consistent with the diag-
nosis of HUS. He presented with impaired general state
of health with asthenia, nausea and loss of appetite. He
showed elevated blood pressure, generalized oedema and
proteinuria (7 g/day). He was treated with daily plasma ex-
change therapy (PE), and renal function recovered almost
completely with only a slightly elevated serum creatinine
level of ∼120–150 µmol/l (1.4–1.7 g/dl). A renal biopsy
was performed, confirming thrombotic microangiopathy
(TMA) in the glomeruli and arterioles. The further clin-
ical course was characterized by two relapses of HUS (one
following an atypical pneumonia, the second one without
an apparent trigger). Again, daily PE was started. Renal
function partly recovered after the first relapse with an
elevated serum creatinine level of ∼180–220 µmol/l (2.0–
2.5 g/dl). But after the second relapse only one month later,
the patient remained anuric despite PE, and finally ESRD
occurred. Chronic haemodialysis was started in November
2002 (Figure 1A).
Fig. 1. Follow-up before (A) and after transplantation (B). PE = plasma exchange therapy. HUS = haemolytic uraemic syndrome.
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Fig. 2. CFH structure that consists of 20 so-called short consensus repeats
(SCR 1–20) arranged in continuous fashion. On the detail of the most C-
terminal SCR 20 of CFH, the localization of the point mutation (arginine to
cysteine change in position 1210) is shown. CFH= complement factor H.
A comprehensive complement analysis revealed normal
complement factor C3, C4, B, I andH serum concentrations
and the activity of the von Willebrand factor-cleaving pro-
tease (ADAMTS 13) was normal. However, genetic studies
disclosed a heterozygous point mutation in the most C-
terminal short consensus repeat 20 [translation of arginine
to cysteine in amino acid position 1210 (R1210C)] of the
CFH gene (Figure 2), which has been previously identified
in five pedigrees and seven individual patients with aHUS
[11], leading to the diagnosis of functionally deficient CFH
(= loss of binding to endothelial cells).
The patient underwent kidney transplantation from a de-
ceased donor in August 2007. To avoid HUS recurrence,
peri- and postoperative plasma infusions of FFP contain-
ing 45–70 mg blood group-specific proteins/ml were given
as follows: 6 ml/kg before anaesthesia, 6 ml/kg before
unblocking the perfusion of the organ, then 3 ml/kg ev-
ery 6 h for 48 h, followed by daily infusions of 3 ml/kg
in the first week, twice a week for 1 month and there-
after weekly for another month. Immunosuppressive ther-
apy consisted of triple therapywith tacrolimus,mycopheno-
late mofetil and prednisone as well as basiliximab on Day 0
and 4.
Five allograft biopsies were performed between Day 5
and Month 10 post-transplant. The first two biopsies were
done 5 days and 3 weeks post-transplant due to initial de-
layed graft function, and both showed histo-morphological
signs consistent with acute tubular necrosis. Two protocol
biopsieswere done atMonths 3 and 6 post-transplant, which
demonstrated polyoma BK virus-associated nephropathy
(i.e. numerous SV40-antigen-positive tubular epithelial
cells). Immunosuppressive therapy was continuously re-
duced and after BK viraemia became negative, the fifth
biopsy done 10 months post-transplant confirmed the res-
olution of polyoma BK virus-associated nephropathy. Im-
portantly, all five allograft biopsies revealed no histological
features of TMA.
Furthermore, blood examinations demonstrated no sings
consistent with TMA during the follow-up [normal lactate
dehydrogenase (LDH), no thrombocytopenia, no schisto-
cytes and normal haptoglobin] with the exception of an el-
evated LDH during an episode of campylobacter enteritis,
which was treated with antibiotics and prophylactic admin-
istration of FFP. A 1-year follow-up showed stable graft
function (Figure 1B).
Discussion
One year post-transplant, there is no evidence ofHUS recur-
rence after single kidney transplantation in this patient with
a CFH gene mutation. However, caution is necessary, and
the patient has to be followed closely. Our strategy of pre-
ventive plasma infusions may have avoided recurrence of
the disease and allowed successful transplantation. Indeed,
the kidney endothelial cells are particularly vulnerable im-
mediately after transplantation in patients with aHUS due to
CFH and other complementmutations, as ischaemia is a po-
tent trigger of complement activation. We know that aHUS
flares were responding to plasma exchange in this patient
(probably more to the plasma infusion than to the extraction
of the patient’s plasma as suggested by Remuzzi et al. [6]).
We have not continued the infusions of plasma after the
second month, and the patient is certainly again at risk for
recurrence. Platelets, blood counts and renal function are
monitored closely, and any infection is controlled as well.
It is not possible to be certain that plasma infusions pre-
vented an HUS episode, but previous attempts to transplant
similar patients have been rather disappointing due to im-
mediate or late recurrence followed by graft loss. For exam-
ple, Martinez-Barricarte et al. [11] reported four patients
who had been transplanted, and three of them had a recur-
rence in the allograft (twowithin 1 year after transplantation
and one patient 27 months after transplantation). A unique
case report is not sufficient to change the proposals made
recently [10]. However, the strategy used here suggests that
combined liver–kidney transplantation is not an absolute
requirement for successful transplantation in patients with
CFH gene mutations. Furthermore, the humanized mon-
oclonal C5 antibody (eculizumab) might be a promising
treatment option for aHUS [12–13], which could also fa-
cilitate single kidney transplantation in these patients in the
future.
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